Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Home Based Exercise for Patients With Breast or Prostate Cancer (The BENEFIT-CA Study) (BENEFIT-CA)

5. august 2022 oppdatert av: Hospital de Clinicas de Porto Alegre

Home Based Exercise for Patients With Breast or Prostate Cancer During Treatment: a Feasibility Trial (The BENEFIT-CA Study)

The purpose of this trial is to evaluate the feasibility of a home based exercise program for individuals with breast or prostate cancer patients undergoing active treatment.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

This feasibility trial aims to assess a home-based exercise program, including a 3-month intervention of structured physical activity and health education for individuals with breast or prostate cancer. The main objective of this trial is to assess the adherence of cancer patients to a program of structured exercise, mixed with a health education approach, implemented and accompanied in a remote approach.

The data collection will include variables related to: (a) recruitment and retentions rates; (b) attendance to exercise sessions; (c) fatigue and quality of life levels; (d) functional capacity levels; (e) adverse events related or not to the study; (f) patient selected outcomes.

Studietype

Intervensjonell

Registrering (Forventet)

80

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

  • Navn: Larissa Xavier Neves da Silva, Master
  • Telefonnummer: 555133596332
  • E-post: larissaxns@gmail.com

Studiesteder

  • Brasil
    • Rio Grande Do Sul
      • Porto Alegre, Rio Grande Do Sul, Brasil, 90035-007
        • Rekruttering
        • Hospital de Clinicas de Porto Alegre
        • Ta kontakt med:
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • eighteen years old minimum;
  • be living in Porto Alegre or metropolitan region;
  • breast cancer stage 0 - III OR
  • localized prostate cancer;
  • undergoing hormonal treatment / manipulation in isolation or combined with other therapies three months prior to the entrance in the study;
  • hormonal therapy / manipulation planned to be active throughout the study duration;
  • not engaged in any exercise training for more than once a week for the past 6 months;
  • in case of previous surgical procedure, the patient must have medical clearance at the moment of the contact to begin the study or be cleared to do so in the near future (up to two weeks).

Exclusion Criteria:

  • metastatic phase / progression of the disease or active regional location prior to beginning of the study;
  • inability to understand the terms and conditions of study due to language, hearing, cognitive or severe psychiatric issues;
  • another family member, who lives at the same residence, participating in the study;
  • planning to move or major absence (more than two weeks) during the study;
  • history of cardiovascular disease (except controlled hypertension) or severe cardiopulmonary disease, as well as history of heart attack, revascularization procedures, profound venous thrombosis, encephalic vascular accident (brain stroke) or pulmonary embolism in the past twelve months;
  • chronic pulmonary disease that requires oxygen or corticosteroid therapy;
  • kidney disease with or that is going to begin the use of dialysis or waiting for a kidney transplant;
  • severe nausea, anorexia or any other condition which does not allow to perform physical exercise;
  • medical contraindication to exercise training.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Home-based exercise program
This is a single study arm consisting of a home-based exercise program for individuals with breast or prostate cancer during active treatment.
Annen: Home based exercise training
The intervention will be based on a remote approach, lasting 12 weeks. The training routine will consist of aerobic (walking), muscle strengthening and stretching exercises, with a frequency of three days per week. The contents related to the exercise prescription will be made available by phone call, text messages and short videos for exercise demonstration.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Trial adherence
Tidsramme: Up to12 weeks.
Proportion of self-reported exercise episodes (out of 36 episodes, total) during the study.
Up to12 weeks.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Recruitment yields
Tidsramme: Up to 8 weeks before allocation to the study intervention.
Proportion of included participants (who signed the informed consent) in relation to the total number of screened individuals for eligibility.
Up to 8 weeks before allocation to the study intervention.
Adverse events throughout the study
Tidsramme: Up to 12 weeks.
Self-reported adverse events, related or not to the study. These measures will be mostly received by phone calls or text messaging.
Up to 12 weeks.

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Fatigue levels at baseline and at the end of the study
Tidsramme: Baseline; Week 12.
Fatigue scores using specific questionnaires of Functional Assessment of Cancer Therapy (FACT questionnaire) for breast or prostate cancer patients.
Baseline; Week 12.
Quality of life, based on the Functional Assessment of Cancer Therapy (FACT questionnaire)
Tidsramme: Baseline; Week 12.
Quality of life scores using specific questionnaires of FACT (Functional Assessment of Cancer Therapy) for breast or prostate cancer patients.
Baseline; Week 12.
Walking capacity
Tidsramme: Baseline; Week 12.
Total distance (in meters) performed during the six minute walk test.
Baseline; Week 12.
Handgrip strength
Tidsramme: Baseline; Week 12.
Maximum strength (in kgf) achieved by both hands in a handgrip test using a hand dynamometer.
Baseline; Week 12.
Abdominal circumference
Tidsramme: Baseline; Week 12.
Anthropometric measure of the highest abdominal circumference, using a metallic measuring tape.
Baseline; Week 12.
Physical activity levels
Tidsramme: Single assessment at baseline.
Physical activity calculated in minutes and intensity per week, of physical activity using the International Physical Activity Questionnaire (IPAQ).
Single assessment at baseline.
Patient selected outcomes
Tidsramme: Week 12.
Through the development of the study, participants will be asked to engage in a focal group to discuss outcomes relevant to be assessed in trials with exercise interventions targeted for patients with breast or prostate cancer.
Week 12.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Hospital de Clinicas de Porto Alegre

Etterforskere

  • Hovedetterforsker: Daniel Umpierre de Moraes, PhD, Hospital de Clinicas de Porto Alegre

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

7. april 2022

Primær fullføring (Forventet)

30. desember 2023

Studiet fullført (Forventet)

30. desember 2023

Datoer for studieregistrering

Først innsendt

7. februar 2022

Først innsendt som oppfylte QC-kriteriene

25. februar 2022

Først lagt ut (Faktiske)

28. februar 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. august 2022

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. august 2022

Sist bekreftet

1. august 2022

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 2021-0262

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

Ja

IPD-planbeskrivelse

Files will be as de-identified as possible before public data sharing. After data protection and data handling routines, de-identified data will be readily available to all project contributors. We consider research data gathered from data collection from research participants pertains primarily to these individuals. Therefore, all individual data will be available to their owners throughout the project. Structured data that will result from this research project will pertain to the PI (Daniel Umpierre), who will be responsible for data integrity, and to the institution (Hospital de Clinicas de Porto Alegre).

The specific structure for data sharing as well as plataforms are still to be defined. As soon, we define the remaining details of our data sharing strategy the IPD plan will be updated.

IPD-delingstidsramme

Due to space and management constraints, we are planning:

  1. To retain and store project documentation (informed consents, IRB communication, subjects' communication) for at least 10 years after the study completion (anticipated time: up to 2033).
  2. To retain and share project resources (instruments, intervention materials) as long as public repositories (e.g., Zenodo, OSF, figshare) provide sharing services at no cost.
  3. To retain and share datasets as long as public repositories (e.g., Zenodo, OSF, figshare) provide sharing services at no cost.

Tilgangskriterier for IPD-deling

All the files will be password-protected and only investigators or data managers designated to use the files will be given access. Different passwords will be used for different users, which allows auditing to be made more easily. Although we do not plan to request justification to release the datasets, we do plan to share the data in a controlled approach. Therefore, once the datasets are made available at the Zenodo.org platform, only registered users will be able to download files. This procedure allows us to keep a record of data requests.

IPD-deling Støtteinformasjonstype

  • Studieprotokoll
  • Informert samtykkeskjema (ICF)
  • Klinisk studierapport (CSR)
  • Analytisk kode

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere